The biotechnology firm Prolynx has raised $70 million in a series A fundraising to develop weight-loss drugs that require less frequent dosing. cen.acs.org/pharmaceutic... #chemsky 🧪
ProLynx raises $70 million to develop its long-lasting weight-loss drug pipeline
The California biotech aims to make its mark on the market with chemistry that can extend the half-life of drugs like semaglutide by at least a month
cen.acs.org
January 3, 2026 at 8:12 PM
The biotechnology firm Prolynx has raised $70 million in a series A fundraising to develop weight-loss drugs that require less frequent dosing. cen.acs.org/pharmaceutic... #chemsky 🧪
Prolynx has raised a $70M Series A & appointed Chris Boulton as CEO. Backed by 5AM Ventures, OrbiMed, and Monograph Capital, we’re advancing ultra-long-acting therapies designed for monthly and quarterly dosing in obesity & metabolic diseases. More: bit.ly/4a6LdhP #biosky
December 11, 2025 at 12:04 PM
Prolynx has raised a $70M Series A & appointed Chris Boulton as CEO. Backed by 5AM Ventures, OrbiMed, and Monograph Capital, we’re advancing ultra-long-acting therapies designed for monthly and quarterly dosing in obesity & metabolic diseases. More: bit.ly/4a6LdhP #biosky
The biotechnology firm ProLynx has raised $70 million in a series A fundraising to develop weight-loss drugs that require less frequent dosing. cen.acs.org/pharmaceutic... #chemsky 🧪
ProLynx raises $70 million to develop its long-lasting weight-loss drug pipeline
The California biotech aims to make its mark on the market with chemistry that can extend the half-life of drugs like semaglutide by at least a month
cen.acs.org
December 13, 2025 at 1:33 PM
The biotechnology firm ProLynx has raised $70 million in a series A fundraising to develop weight-loss drugs that require less frequent dosing. cen.acs.org/pharmaceutic... #chemsky 🧪
Prolynx Appoints Amer Mirza, PhD, as New Chief Scientific Officer to Propel Drug Development#USA#Emeryville#ProLynx#Slone_Partners#Amer_Mirza
Prolynx Appoints Amer Mirza, PhD, as New Chief Scientific Officer to Propel Drug Development
Prolynx has appointed Dr. Amer Mirza as its new Chief Scientific Officer. His deep expertise in drug discovery will be vital for advancing innovative therapies.
third-news.com
July 16, 2026 at 8:02 AM
Prolynx Appoints Amer Mirza, PhD, as New Chief Scientific Officer to Propel Drug Development#USA#Emeryville#ProLynx#Slone_Partners#Amer_Mirza
While current obesity medicines have transformed care, many patients still discontinue treatment due to side effects. See how @prolynxinc.com is working on next-generation therapies designed to stay active for months. @amdiabetesassn.bsky.social #ADASciSessions https://youtu.be/9KbHxi8l2hs
The Future of Obesity Treatment | Prolynx
Prolynx is redefining what’s possible in obesity treatment. Despite major advances with once-weekly GLP-1 therapies, pat
youtu.be
June 9, 2026 at 12:54 PM
While current obesity medicines have transformed care, many patients still discontinue treatment due to side effects. See how @prolynxinc.com is working on next-generation therapies designed to stay active for months. @amdiabetesassn.bsky.social #ADASciSessions https://youtu.be/9KbHxi8l2hs
Thurs news: Lilly’s next gen obesity drug delivers strong weight loss + reduced knee pain. Pfizer is not done with M&A. Prolynx gets funding for long lasting obesity drugs. Intuitive wins expanded uses for da Vinci system. Will 2026 be a breakout year for M&A? —https://bit.ly/3JeBlY5
December 11, 2025 at 4:58 PM
Thurs news: Lilly’s next gen obesity drug delivers strong weight loss + reduced knee pain. Pfizer is not done with M&A. Prolynx gets funding for long lasting obesity drugs. Intuitive wins expanded uses for da Vinci system. Will 2026 be a breakout year for M&A? —https://bit.ly/3JeBlY5
#RNAinterference drug developer #SanegeneBio leads our round-up of this week's #biotechfinancings, with a $110 million Series B backed by recent partner #EliLilly.
pharmaphorum.com/news/sanegen...
pharmaphorum.com/news/sanegen...
SanegeneBio raises $110m for RNAi, plus other financings
Biotech financings this week include SanegeneBio's Lilly-backed $110m Series B, with Sidera, D3 Bio, BlossomHill, and Prolynx also raising new funds.
pharmaphorum.com
December 12, 2025 at 10:22 AM
#RNAinterference drug developer #SanegeneBio leads our round-up of this week's #biotechfinancings, with a $110 million Series B backed by recent partner #EliLilly.
pharmaphorum.com/news/sanegen...
pharmaphorum.com/news/sanegen...
Feed: "Endpoints News"
By: Kyle LaHucik on Thursday, December 11, 2025
By: Kyle LaHucik on Thursday, December 11, 2025
Weight loss biotech Prolynx gets $70M, snags Amgen's obesity commercial leader as CEO
5AM Ventures and OrbiMed have co-led a $70 million Series A for Prolynx, which is developing long-acting obesity drugs.
endpoints.news
December 12, 2025 at 1:08 AM
Feed: "Endpoints News"
By: Kyle LaHucik on Thursday, December 11, 2025
By: Kyle LaHucik on Thursday, December 11, 2025
ProLynx Unveils Groundbreaking Once Monthly Semaglutide for Weight Management#United_States#San_Francisco#biotechnology#ProLynx#Semaglutide
ProLynx Unveils Groundbreaking Once Monthly Semaglutide for Weight Management
ProLynx Inc. announces a major advancement with its once monthly semaglutide, showcased in PNAS. The innovative therapy achieves significant weight loss with fewer injections.
third-news.com
December 2, 2024 at 12:45 PM
ProLynx Unveils Groundbreaking Once Monthly Semaglutide for Weight Management#United_States#San_Francisco#biotechnology#ProLynx#Semaglutide
LucidQuest Views >>> Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity candidates Comment below! #LucidQuest #PharmaCI
Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity candidates
Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity candidates Professional audiences only. Not investment research or advice. UK […]
The post Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity candidates appeared first on LucidQuest Ventures.
dlvr.it
December 14, 2025 at 7:34 PM
LucidQuest Views >>> Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity candidates Comment below! #LucidQuest #PharmaCI
In pursuit of ultra-long-acting obesity meds, Prolynx raises $70M, taps Amgen vet $AMGN firstwordpharma.com/story/6739500
December 12, 2025 at 12:19 AM
In pursuit of ultra-long-acting obesity meds, Prolynx raises $70M, taps Amgen vet $AMGN firstwordpharma.com/story/6739500